Efficacy of osimertinib and histomolecular profile at progression in EGFR-mutated lung cancer
C. Mehlman (Boulogne-Billancourt, France), J. Cadranel (Paris, France), R. Lacave (Paris, France), G. Rousseau-Bussac (Creteil, France), A. Pujals (Creteil, France), N. Girard (Paris, France), I. Bieche (Paris, France), V. Gounant (Paris, France), N. Théou-Anton (Paris, France), S. Friard (Suresnes, France), J. Trédaniel (Paris, France), H. Blons (Paris, France), C. Dujon (Versailles, France), B. Duchemann (Bobigny, France), P. Schischmanoff (Bobigny, France), T. Chinet (Boulogne-Billancourt, France), E. Giroux Leprieur (Boulogne-Billancourt, France)
Source: International Congress 2019 – Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Poster Discussion
Number: 370
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Mehlman (Boulogne-Billancourt, France), J. Cadranel (Paris, France), R. Lacave (Paris, France), G. Rousseau-Bussac (Creteil, France), A. Pujals (Creteil, France), N. Girard (Paris, France), I. Bieche (Paris, France), V. Gounant (Paris, France), N. Théou-Anton (Paris, France), S. Friard (Suresnes, France), J. Trédaniel (Paris, France), H. Blons (Paris, France), C. Dujon (Versailles, France), B. Duchemann (Bobigny, France), P. Schischmanoff (Bobigny, France), T. Chinet (Boulogne-Billancourt, France), E. Giroux Leprieur (Boulogne-Billancourt, France). Efficacy of osimertinib and histomolecular profile at progression in EGFR-mutated lung cancer. 370
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: